It has been proposed that CVD is more prevalent in older patients, as these patients are more likely to have impaired immune systems that loses the ability to responds effectively to infections and the reduced levels of ACE2 observed among the elderly may predispose older patients to more severe complications of COVID-19 due to loss of the protective effects of ACE2 to regulate and control inflammation. This evidence concerns the gene ACE2 and COVID-19.